These two biotech stocks are poised for big gains next year.
News & Analysis: Heron Therapeutics
A high-risk transformative move sent one of these stocks lower.
You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.
These three biotech stocks might be outstanding buys right now.
Amarin and Heron Therapeutics could turn out to be outstanding bargains.
These stocks are bargains.
Heron's falling share price last month turned out to be a bad omen.
Heron's pain is Pacira's gain.
April's about to shower biopharma investors with important updates that could move these stocks.
Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.